SavedAdd your journal

Journals / Adıyaman Üniversitesi Fen Bilimleri Dergisi / 2021 / Cilt: 11 - Sayı: 1

Analysis of Interactions of NHC Type Molecules and NHC-Ag Complexes with VEGFR-2 and DNA: A Molecular Docking Study

NHC Tipi Moleküllerin ve NHC-Ag Komplekslerin VEGFR-2 ve DNA ile Etkileşimlerinin Analizi: Moleküler Doking Çalışması

Elvan ÜSTÜN
Neslihan ŞAHİN
Pages
113–125
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, the interaction of 1-allyl-3-benzylbenzimidazolium, 1-allyl-3-(naphthylmethyl)benzimidazolium, 1-allyl-3-(anthracen-9-ylmethyl)benzimidazolium,chloro[1-allyl-3-benzylbenzimidazolium-2-ylidene]silver(I), chloro[1-allyl-3-(naphthylmethyl)benzimidazolium-2-ylidene]silver(I), chloro[1-allyl-3-(anthracen-9-ylmethyl)benzimidazolium-2-ylidene]silver(I) with VEGFR-2 and DNA were analyzed bymolecular docking methods.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Molecular docking is an important tool in drug research.
📊
Key Findings & Data:One of these receptors is VEGFR-2.
💡
Conclusion & Impact:In this study, the interaction of 1-allyl-3-benzylbenzimidazolium, 1-allyl-3-(naphthylmethyl)benzimidazolium, 1-allyl-3-(anthracen-9-ylmethyl)benzimidazolium,chloro[1-allyl-3-benzylbenzimidazolium-2-ylidene]silver(I), chloro[1-allyl-3-(naphthylmethyl)benzimidazolium-2-ylidene]silver(I), chloro[1-allyl-3-(anthracen-9-ylmethyl)benzimidazolium-2-ylidene]silver(I) with VEGFR-2 and DNA were analyzed bymolecular docking methods.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Molecular docking is an important tool in drug research. Thanks to these calculations, thetype and magnitude of interactions of the molecules with target molecules are evaluated. It is alsopossible to perform more detailed analyzes than known experimental methods in an easy andeconomical way by using the results obtained with current scientific developments and examineinteractions with different target molecules depending on bioactivity type. Cancer researchesshow that vascular endothelial growth factor is effective in the growth and proliferation of cancercells. Inhibition of the receptor that regulates the release of this factor may be an efficient methodfor designing an anticancer agent. One of these receptors is VEGFR-2. This receptor can be usedas a target molecule in cancer research. In addition, the interaction of molecules with DNA isimportant in terms of getting insight for future studies. In this study, the interaction of 1-allyl-3-benzylbenzimidazolium, 1-allyl-3-(naphthylmethyl)benzimidazolium, 1-allyl-3-(anthracen-9-ylmethyl)benzimidazolium,chloro[1-allyl-3-benzylbenzimidazolium-2-ylidene]silver(I), chloro[1-allyl-3-(naphthylmethyl)benzimidazolium-2-ylidene]silver(I), chloro[1-allyl-3-(anthracen-9-ylmethyl)benzimidazolium-2-ylidene]silver(I) with VEGFR-2 and DNA were analyzed bymolecular docking methods.

Özet

Moleküler doking, ilaç araştırmalarında önemli bir araçtır. Bu hesaplamalar sayesinde moleküllerin hedef moleküllerle olan etkileşimlerinin türü ve büyüklüğü değerlendirilir. Güncel bilimsel gelişmelerle elde edilen sonuçlar kullanılarak, bilinen deneysel yöntemlere göre daha detaylı analizleri kolay ve ekonomik bir şekilde gerçekleştirmek ve biyoaktivite tipine bağlı olarak farklı hedef moleküller ile etkileşimleri incelemek de mümkündür. Kanser araştırmaları vasküler endotelyal büyüme faktörünün, kanser hücrelerinin büyümesi ve çoğalmasında etkili olduğunu göstermektedir. Bu faktörün salımını düzenleyen reseptörün inhibisyonu, bir antikanser ajanı tasarlamak için etkili bir yöntem olabilir. Bu reseptörlerden biri VEGFR-2'dir. Bu reseptör, kanser araştırmalarında bir hedef molekül olarak kullanılabilir. Ayrıca moleküllerin DNA ile etkileşimi ileride yapılacak çalışmalara ışık tutması açısından önemlidir. Bu çalışmada, VEGFR2 ve DNA ile 1-allil-3-benzilbenzimidazolyum, 1-allil-3-(naftilmetil)benzimidazolyum, 1-allil-3 (antrasen-9-il-metil)benzimidazolyum, kloro[1-allil-3-benzilbenzimidazolyum-2- iliden]gümüş(I), kloro[1-allil-3-(naftilmetil)benzimidazolyum-2-iliden]gümüş (I), kloro[1-allil3-(antrasen-9-il-metil)benzimidazolium-2-iliden]gümüş(I) bileşiklerinin etkileşimi moleküler doking yöntemleriyle analiz edildi.

🔖

Cite This Article

ÜSTÜN, E., ŞAHİN, N. (2022). Analysis of Interactions of NHC Type Molecules and NHC-Ag Complexes with VEGFR-2 and DNA: A Molecular Docking Study. Adıyaman Üniversitesi Fen Bilimleri Dergisi, Cilt: 11 - Sayı: 1, 113–125. https://ajindex.com/articles/428399

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Auerbach, W., Auerbach, R., Angiogenesis inhibition: a review, Pharmacology & Therapeutics, 63(3), 265-311, 1994
  2. Otrock, Z.K., Mahfouz, R.A., Makarem, J.A., Shamseddine, A.I., Understanding the biology of angiogenesis: review of the most important molecular mechanisms, Blood Cells, Molecules, and Diseases, 39(2), 212-220, 2007
  3. Weidner, N., Tumor angiogenesis: review of current applications in tumor prognostication, In Seminars in Diagnostic Pathology, 10(4), 302-313, 1993
  4. Shahi, P.K., Pineda, I.F., Tumoral angiogenesis: review of the literature, Cancer Investigation, 26(1), 104-108, 2008
  5. Ferrara, N., Vascular endothelial growth factor and the regulation of angiogenesis, Recent Progress in Hormone Research, 55, 15-35, 2000
  6. Chung, A.S., Ferrara, N., Developmental and pathological angiogenesis, Annual Review of Cell and Developmental Biology, 27, 563-584, 2011
  7. Matulonis, U.A., Berlin, S., Ivy, P., Tyburski, K., Krasner, C., Zarwan, C., Lee, H., Cediranib, An oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer, Journal of clinical oncology, 27(33), 5601-5606, 2009
  8. Parr, C., Watkins, G., Boulton, M., Cai, J., Jiang, W.G., Placenta growth factor is overexpressed and has prognostic value in human breast cancer, European Journal of Cancer, 41(18), 2819-2827, 2005
  9. Strumberg, D., Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment, Drugs Today (Barc), 41(12), 773-784, 2005
  10. Zhang, P.C., Liu, X., Li, M.M., Ma, Y.Y., Sun, H.T., Tian, X.Y., Chen, H.Y., AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo, Biochemical Pharmacology, 172, 113771, 2020
  11. Sana, S., Reddy, V.G., Bhandari, S., Reddy, T.S., Tokala, R., Sakla, A.P., Shankaraiah, N., Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect, European Journal of Medicinal Chemistry, 112457, 2020
  12. Abdel-Mohsen, H.T., Abdullaziz, M.A., Kerdawy, A.M.E., Ragab, F.A., Flanagan, K.J., Mahmoud, A.E., Senge, M.O., Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1, 2- Disubstituted Benzimidazoles, Molecules, 25(4), 770, 1-37, 2020
  13. El- Adl, K., El- Helby, A.G.A., Sakr, H., Ayyad, R.R.,